Schizochytrium sp.,a marine microalga,is a potential source of edible oil due to its short growth cycle and rapid lipid accumulation,especially of docosahexaenoic acid.An approach to isolate edible microalgal oil from Schizochytrium sp.using aqueous enzymatic extraction(AEE)was developed.Parameters were optimized by single-factor experiments followed by Box-Behnken design.Proteases were effective in extracting oil.The maximum free oil recovery(49.7%±0.58%)and total oil recovery(68.1%±0.94%)were obtained under optimum conditions of liquid-to-solid ratio of 4.8:1,a 2.5%enzyme concentration of papain and an extraction time of 2.2 h.There was a significant difference(P<0.05)in polyunsaturated fatty acid composition between microalgal oil obtained by AEE and by Soxhlet extraction,with the former having superior physiochemical properties and higher concentrations of bioactive components including total phenolic compounds and total tocopherols.These findings indicate a potential application of AEE for extraction of oil from Schizochytrium sp.
Biochanin A(BCA) and CPe-Ⅲ peptide, which both exist in chickpea(Cicer arietinum L.), possess significant antihyperlipidemic properties. However, the actualmechanisms ofthose compounds in inhibiting the dysregulation oflipid metabolism and complicated inflammation have not been wellcharacterized. This study investigated the effects ofBCA, CPe-Ⅲ peptide, and combined BCA and CPe-Ⅲ peptide(BC) on the expression ofgenes involved in hepatic lipid and inflammation metabolism. Results demonstrated that BCA, CPe-Ⅲ peptide, and BC significantly attenuated hepatitis and hyperlipidemia by downregulating those genes involved in pro-inflammatory cytokines(TNF-α), hepatic fatty acid(FA) synthesis(ACC1 and FAS), cholesterolmetabolism(SREBP2, HMGCR, and PCSK9), and upregulating key regulators involved in FA oxidation(PPARα and FABP1), lipolysis(ATGL), LDLR, reverse cholesteroltransport(ABCA1, SR-B1, and LXRα), and cholesterolcatabolism(CYP7 A1). Moreover, they also altered the expression oflipid metabolism-related proteins, including SREBP2, PCSK9, LDLR, ABCA1, and CYP7 A1. Finally, these results revealed that the combination treatment ofBCA and CPe-Ⅲ peptide resulted in greater antihyperlipidemic activity compared with individualcompounds.
